Timothy Stevens, PA
Medical · Mt Pleasant, UTNPI 1417201419
Payments from drug & device makers
Across 157 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$491
- Boehringer Ingelheim$318
- Nestle Healthcare Nutrition Inc.$247
- Axsome Therapeutics, Inc.$207
- Pfizer$200
- Lilly USA, LLC$187
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,64396%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $491 |
| Boehringer Ingelheim | 19 | $318 |
| Nestle Healthcare Nutrition Inc. | 13 | $247 |
| Axsome Therapeutics, Inc. | 9 | $207 |
| Pfizer | 15 | $200 |
| Lilly USA, LLC | 14 | $187 |
| Xeris Pharmaceuticals, Inc. | 9 | $177 |
| AstraZeneca | 9 | $158 |
| Astellas Pharma US Inc | 1 | $100 |
| Novo Nordisk | 5 | $91 |
| Supernus Pharmaceuticals, Inc. | 4 | $88 |
| Abbott | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Amgen | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $48 |
| Alkermes, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Vertex | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Exact Sciences | 1 | $16 |
| Cranial Technologies, Inc | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$2,743 in reported general payments places this provider in the 70th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $15,038 |
| XareltoRivaroxaban | 23 | $14,400 |
| MyrbetriqMirabegron | 23 | $14,216 |
| TrulicityDulaglutide | 14 | $13,368 |
| GlyxambiEmpagliflozin/Linagliptin | 19 | $12,770 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $11,309 |
| TrintellixVortioxetine Hydrobromide | 18 | $9,717 |
| JardianceEmpagliflozin | 11 | $9,612 |
| Oxycodone Hcl | 138 | $5,718 |
| Fentanyl | 34 | $3,636 |
| Gabapentin | 103 | $2,380 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 30 | $2,315 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 60 | $2,228 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,918 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 40 | $1,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimGlyxambi, Stiolto Respimat, Jardiance | $318 | $33,69050 claims |
| PfizerEliquis | $200 | $15,03813 claims |
| Johnson & JohnsonXarelto | $25 | $14,40023 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $14,21623 claims |
| Lilly USA, LLCTrulicity | $187 | $13,36814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $61 | $9,71718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 263 medical providers in Utah.
Other medical in Mt Pleasant
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$65K
- Val WarnerLayton$51K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
- Mark UdySt George$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.